IP Library Granted Patent US 7,396,842
Granted Patent B2
US 7,396,842 · App. 11/111,845 · Granted Jul 8, 2008

Five-membered cyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,396,842
App. No.
11/111,845
Granted
Jul 8, 2008
Kind
B2
Abstract

A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R 1 is hydrogen, substituted or unsubstituted alkyl, etc., R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y 1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH 2 ) n —, etc., the wavy line means (E)-configuration or (Z)-configuration, R 3 is substituted or unsubstituted aryl, etc., Y 2 is substituted or unsubstituted alkylene, etc., R 4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R 5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.

Claims (47)

1. A compound of the formula:

wherein X is a sulfur atom,

R 1 is a hydrogen atom, a substituted or unsubstituted alkyl, or a substituted or unsubstituted aryl,

R 2 is a hydrogen atom, a substituted or unsubstituted alkyl, or a substituted or unsubstituted aryl,

Y 1 is a direct bond, a substituted or unsubstituted alkylene, —CO(CH 2 ) n —, —SO 2 (CH 2 ) n —, —CONH(CH 2 ) n —, —CSNH(CH 2 ) n —, or —COO(CH 2 ) n —,

n is an integer of from 0 to 5,

the wavy line means (E)-configuration or (Z)-configuration,

R 3 is a substituted or unsubstituted pyridyl,

Y 2 is a substituted or unsubstituted alkylene, or an alkenylene,

R 4 is a hydrogen atom, a substituted or unsubstituted alkanoyl, a substituted or unsubstituted alkyl, —COOR 8 , —SO 2 R 9 , —COR 10 , —CON(R 11 )R 12 , —CSN(R 13 )R 14 , a cycloalkyl, a substituted or unsubstituted aryl, or —C(═NH)N(R 15 )R 16 ,

R 5 is a hydrogen atom, or a substituted or unsubstituted alkyl,

R 8 is a substituted or unsubstituted alkyl, a cycloalkyl, or a substituted or unsubstituted aryl,

R 9 is a substituted or unsubstituted alkyl, or a substituted or unsubstituted aryl,

R 10 is a cycloalkyl, or a substituted or unsubstituted aryl,

R 11 is a hydrogen atom or an alkyl,

R 12 is a hydrogen atom, a substituted or unsubstituted alkyl, a cycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted arylcarbonyl,

R 13 is a hydrogen atom or an alkyl,

R 14 is a hydrogen atom, a substituted or unsubstituted alkyl, a cycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted arylcarbonyl,

R 15 is a hydrogen atom or an alkyl,

R 16 is a hydrogen atom or a substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

2. The compound according to claim 1 , which is a compound of the formula:

wherein X is a sulfur atom,

R 1 is a hydrogen atom; an alkyl; an alkyl being substituted by a hydroxy group or a halogen atom; an aryl; or an aryl which is substituted by one or more groups selected from the group consisting of an alkoxy, a halogen-substituted alkoxy, a hydroxy, a halogen atom, a cyano, an amino, a mono- or di-(alkyl)amino, a nitro, an alkyl, an alkyl being substituted by a halogen atom or a hydroxy, a cycloalkyl, a cycloalkyl-substituted alkyl, a methylenedioxy, an ethylenedioxy, a carboxy, an alkoxycarbonyl, a carbamoyl, an alkylcarbamoyl, a di(alkyl)carbamoyl, an alkylthio, an alkylsulfinyl, an alkylsulfonyl, a sulfamoyl, an alkylsulfamoyl, a di(alkyl)sulfamoyl, an aryl, and an aryl being substituted by an alkyl, an alkoxy, a halogen atom or a hydroxy; R 2 is a hydrogen atom; an alkyl; an alkyl being substituted by a hydroxy, a halogen atom or an amino; an aryl; or an aryl being substituted by one or more groups selected from the group consisting of an alkoxy, a halogen-substituted alkoxy, a hydroxy, a halogen atom, a cyano, an amino, a mono- or di-(alkyl)amino, a nitro, an alkyl, an alkyl being substituted by a halogen atom or a hydroxy, a cycloalkyl, a cycloalkyl-substituted alkyl, methylenedioxy, ethylenedioxy, a carboxy, an alkoxycarbonyl, a carbamoyl, an alkylcarbamoyl, a di(alkyl)-carbamoyl, an alkylthio, an alkylsulfinyl, an alkylsulfonyl, sulfamoyl, an alkylsulfamoyl, a di(alkyl)sulfamoyl, an aryl, and an aryl being substituted by an alkyl, an alkoxy, a halogen atom, or a hydroxy;

Y 1 is a direct bond; a straight chain or branched chain C 1 -C 5 alkylene; a straight chain or branched chain C 1 -C 5 alkylene being substituted by a hydroxy, a halogen atom or an amino; —CO(CH 2 ) n —; or —SO 2 (CH 2 ) n —(n is an integer of from 0 to 5),

R 3 is a pyridyl or a pyridyl being substituted by an alkyl, an alkoxy, a halogen atom or a hydroxy,

Y 2 is a straight chain or branched chain C 2 -C 5 alkylene; a straight chain or branched chain C 2 -C 5 alkylene being substituted by a hydroxy, an alkoxy, a halogen atom, an amino or an alkanoylamino; or a straight chain or branched chain C 3 -C 5 alkenylene,

R 4 is a hydrogen atom; an alkanoyl; an aroyl; an alkyl; an alkyl being substituted by a hydroxy, an alkoxy, a halogen atom or an amino: an alkylcarbamoyl; an alkoxycarbonyl; an alkylaminothiocarbonyl; an alkylsulfonyl; an arylsulfonyl; or an alkyl-substituted arylsulfonyl,

R 5 is a hydrogen atom; an alkyl; or an alkyl being substituted by a hydroxy, a halogen atom or an amino, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

3. The compound according to claim 1 or 2 , wherein Y 1 is a direct bond, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

4. The compound according to claim 1 or 2 , wherein R 1 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

5. The compound according to claim 1 or 2 , wherein R 2 is a substituted or unsubstituted aryl, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

6. The compound according to claim 1 or 2 , wherein Y 1 is a direct bond or a —CO—, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

7. The compound according to claim 1 or 2 , wherein the wavy line means (Z)-configuration, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

8. The compound according to claim 1 or 2 , wherein Y 2 is ethylene or trimethylene, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

9. The compound according to claim 1 or 2 , wherein R 4 is a substituted or unsubstituted alkanoyl, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkylcarbamoyl, a substituted or unsubstituted alkylaminothiocarbonyl, or a substituted or unsubstituted alkoxycarbonyl, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

10. The compound according to claim 1 or 2 , wherein R 4 is a substituted or unsubstituted alkanoyl, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkylcarbamoyl, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

11. The compound according to claim 1 or 2 , wherein R 5 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

12. The compound according to claim 1 , which is a compound of the formula:

wherein Ring A is a pyridine ring,

m is 2 or 3,

Y 3 is a direct bond or a carbonyl,

the number of R 17 is 1 or 2, and R 17 s are independently selected from a halogen atom, a C 1 -C 4 alkoxy, a trifluoromethoxy and a methylenedioxy,

the number of R 18 is 1 or 2, and R 18 s are independently selected from a halogen atom, a C 1 -C 4 alkoxy, a trifluoromethoxy and a hydroxy,

R 19 is a C 1 -C 4 alkyl; a C 1 -C 4 alkyl being substituted by a hydroxy, a C 1 -C 4 alkoxy, a mono- or di-(C 1 -C 4 alkyl)amino or a carboxy; a C 1 -C 4 alkylamino; or a C 1 -C 4 alkylamino being substituted by a hydroxy, a C 1 -C 4 alkoxy, a mono- or di-(C 1 -C 4 alkyl)amino, or a carboxy,

or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

13. The compound according to claim 12 , provided that when Y 3 is a direct bond, then R 19 is not a methyl, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

14. A pharmaceutical composition, which comprises the compound as set forth in claim 1 , 2 or 12 , or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Assignments (1)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →